Oneness Biotech advances SNS851 to phase 1 multiple-ascending dose study

The Taiwan-based biotech said it completed the single-ascending dose portion of its phase 1 trial for SNS851 in healthy volunteers and is moving to multiple-ascending dose testing in participants with fatty liver disease. Data from the MAD portion are expected in Q1 2027.